A reader — I’ll call him Jack — recently asked my thoughts on his plans to pursue treatment with lecanemab for his mild cognitive impairment caused by Alzheimer’s disease. So we set up a call to discuss what it is like to live beset by the threat of Alzheimer’s disease, but also the promise of a treatment to slow it.
Jack’s account of his neurologist’s workup and the many steps from diagnosis to anti-amyloid therapy seemed in order. As we explored the details, however, something felt out of order. The problem wasn’t what I was hearing; it was what I wasn’t hearing.
A very important character was missing.
Continue to STAT+ to read the full story…
Berita Terkini
Berita Terbaru
Daftar Terbaru
News
Berita Terbaru
Flash News
RuangJP
Pemilu
Berita Terkini
Prediksi Bola
Togel Deposit Pulsa
Technology
Otomotif
Berita Terbaru
Daftar Judi Slot Online Terpercaya
Slot yang lagi gacor
Teknologi
Berita terkini
Berita Pemilu
Berita Teknologi
Hiburan
master Slote
Berita Terkini
Pendidikan
Resep
Jasa Backlink
One Piece Terbaru